LNF1901 not checked
Shandong New Time Pharmaceutical Co., LTD
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LNF1901,7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg,IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.”In the company’s words, NCT06226363 on ClinicalTrials.gov
- Tested for
- Advanced Malignant Tumors
- Main trialPhase 1
- “This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.”In the company’s words, NCT06226363 on ClinicalTrials.gov
Other drugs for Advanced Malignant Tumors
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 1 Feb 2025 | Phase I Study of LNF1901 in Advanced Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026